HEPANTIVIR CLINICAL TRIAL

EVALUATION OF THE EFFICACY OF HEPANTIVIR (SECURININE) IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201507001055177

Enrollment

Registered

2015-03-05

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HEPATITIS HEPATITIS

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Fifty consecutive and consenting patients being managed by gastroenterology unitwith clinical and biochemical features as well as serological evidence of chronic hepatitis B infection and who meet the study criteria- 18 years and above, HBsAg positive with elevated serum ALT, Serum HBV DNA > 2000iu/ml

Exclusion criteria

Exclusion criteria: No consent, presence of underlying liver malignancy, presence of co-morbidities eg end-organ failure

Design outcomes

Primary

Measure	Time frame
improvement in symptoms, laboratory measurement including transaminase and HBV load as well as any adverse event will be compared between the treatment arm and tenofovir using chi sqaure test.	—

Secondary

Measure	Time frame
Absence of HBV DNA	—

Countries

Nigeria

Contacts

Public ContactBOLADE SOREMEKUN

SPONSOR

b.soremekun@bolarpharm.com+2348034499670

Outcome results